



Mithra releases invitation to its extraordinary securities holders' meeting

Liege, Belgium, 23 August 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health today announces the invitation to its extraordinary securities holders' meeting that will be held on **Thursday September 22 2022 at 2:00 PM (CEST)**.

The notice for the extraordinary general meeting including a description of the formalities to participate in the meeting is available on the website investors.mithra.com.

Exceptional organisational arrangements due to Covid-19

Considering the COVID-19 pandemic, it is possible that our governments and public authorities may adapt the conditions and modalities for physical participation in the extraordinary general meeting. We reserve our rights to issue additional instructions in this regard. These measures are in the interest of the health of the individual security holders, as well as of the Company's employees and other persons responsible for organizing the extraordinary general meeting. Therefore, the Company recommends that shareholders of the Company who wish to participate in the extraordinary general meeting use, to the extent possible, the right to vote by mail or by proxy containing specific voting instructions for each proposed decision granted to Fanny Rozenberg, secretary of the Board of Directors of the Company, and not to attend the extraordinary general meeting personally. The Company will grant access to the general meeting to security holders, proxy holders and any other persons only to the extent permitted by the measures taken or to be taken by the authorities, as applicable at the time of the extraordinary general meeting, and always taking into account the recommendations of the authorities, as well as safety and health considerations. In addition, holders of the Company's securities are encouraged to exercise their right to ask questions in writing concerning the items on the agenda of the extraordinary general meeting. Details of how to participate in the extraordinary shareholders' meeting are set out in this notice of meeting.

All procedures for attending the extraordinary shareholders' meetings are indicated in the present meeting's invitation.

Admission requirements

As referred in the meeting's invitation published in the Belgian press, the right to participate in the extraordinary general shareholder's meeting and to vote is subject to the prior registration of the shares under the shareholder's name on **8 September 2022 at midnight (CEST) (the "Record Date")**, either by way of registration on the company's share register, or either by way of registration in book entry form in an account held with a settlement institution or a certified account holder, without taking into account the number of shares held by the shareholder at the day of the extraordinary general meeting. Only persons who are shareholders on the Record Date are entitled to vote at the extraordinary general meeting.

A certification is delivered to the shareholder by the settlement institution or certified account holder which certifies the number of dematerialized shares registered in its accounts under the name of the

shareholder on the Record Date, for which the shareholder has expressed its intention to participate in the extraordinary general meeting.

The shareholder indicates his willingness to participate in the extraordinary general meeting by **16 September 2022** at the latest. This must be done by email to corporate.secretary@mithra.com, or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège.

Right to ask questions

The directors answer questions that are asked by the shareholders, in writing before the meeting, concerning the agenda, in accordance with legal provisions. These questions may be asked prior to the extraordinary general meeting by email to the address corporate.secretary@mithra.com or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège. These questions must be received by the Company on **16 September 2022** at the latest.

Further information relating to the abovementioned right and the modalities for exercising them are available on the Company's website (www.mithra.com).

Proxies

Any shareholder who wish to vote for that meeting shall be represented by a proxy holder determined by the Company.

Shareholders wishing to be represented must send the completed and signed¹ proxy form to the Company on **16 September 2022** at the latest, by email, fax or mail to Mithra's headquarter.

Shareholders wishing to vote by mail must send the completed and signed¹ proxy form to the Company on **16 September 2022** at the latest, by email, fax or mail to Mithra's headquarter.

Further information on the exercise of this right is available on the Company's website (www.mithra.com). The proxy and voting forms may be obtained on the Company's website (www.mithra.com) or upon request at the Company's registered office, or by email to corporate.secretary@mithra.com.

Shareholders wishing to be represented must comply with the registration and confirmation procedure described above.

Available documents

All documents concerning the extraordinary general meeting that are required by law to be made available to shareholders as well as the text of the amended articles of association following the approval of the amendments proposed on the agenda may be consulted on the Company's website (www.mithra.com) as from 23 August 2022. As from the same date, shareholders have the right to consult these documents on business days and during normal office hours, at the Company's registered office and/or, upon display of their securities, obtain copies of these documents free of charge.

Requests for copies may also be made, free of charge, by mail (writing) marked for the attention Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège, or by email to corporate.secretary@mithra.com.

¹ The form must be signed in writing or electronically, with a qualified electronic signature within the meaning of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended

For more information, please contact:**Benoît Mathieu (IRO)** : +32 473 35 80 18 - investorrelations@mithra.com**Maud Vanderthommen (Press)** : +32 473 58 61 04 – press@mithra.com**About Mithra**

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, Mithra is now focusing on its second product Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium.

www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

News Alerts

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)